Compare Cytokinetics Inc (CYTK) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Starbucks Corp — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Starbucks Corp trades at $90.75 (market cap $106.26B). The key difference: Starbucks Corp is far larger — about 12.3× Cytokinetics Inc's market cap, and Starbucks Corp pays a 2.7% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Starbucks Corp for 190 Days on average.
| CYTK | SBUX | |
|---|---|---|
Market Cap | $8.62B | $106.26B |
Volume | 2,594,626 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $108.55 |
52-Week Low | $54.76 | $78.46 |
Typical Hold Time | 19 Days | 190 Days |
Enterprise Value | $8.72B | $125.08B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% today, amid bearish technical signals but strong analyst optimism. The stock shows negative profitability with a -1,321.12% net income margin and P/S ratio of 114, reflecting high growth expectations. Recent Phase 3 trial successes for aficamten in hypertrophic cardiomyopathy position the company for potential FDA approval and commercial expansion, driving the 97% buy rating consensus with a $112.60 price target.
The outlook balances clinical progress against financial strain. While aficamten's recent data and commercial launch of MYQORZO offer significant upside, persistent cash burn and high valuation multiples present substantial risk. Investors face binary outcomes dependent on regulatory success and market penetration versus ongoing operational losses.
Starbucks (SBUX) trades at $93.21, down 0.4% with bearish technical signals. Recent earnings show mixed results with Q2 2026 beating expectations but Q4 2025 missing. The company is undergoing strategic restructuring with 250 store closures announced in September 2026, while maintaining dividend payments. Revenue growth remains modest at $37.18B for 2025 with net income margin at 5.17%. Analyst consensus remains positive with a $115.50 price target despite current bearish technical indicators.
SBUX presents a turnaround opportunity with strong analyst support but faces execution risks from store closures and competitive pressures. The stock trades at premium valuations (P/E 53.88) requiring sustained earnings growth. Near-term volatility expected during restructuring, while long-term prospects depend on successful portfolio optimization and international expansion, particularly in Asian markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
